ASERTI Pharmaceutical
Eliminating Problem Proteins at their Source
ASERTI Pharmaceutical is pioneering SERTI-based therapeutics that degrade harmful proteins before they ever reach their destination unlocking a bold new era in precision medicine.
Problems & Opportunity
Treating devastating diseases at the protein level

Tumor
Cancers
Removing checkpoint proteins that undermine immune system response.

Neurodegenerative Diseases
Blocking secreted proteins and receptors linked to ALS, Alzheimer’s, and other neurodegenerative disorders.

Autoimmune
Disorders
Reducing overactive immune responses by degrading secreted cytokines and surface proteins.

Infectious
Diseases
Disrupting viral proteins before viruses replicate or hijack healthy cells.
Revolutionizing Targeted Protein Degradation
ASERTI is pioneering therapeutic innovation with a bold new class of targeted protein degradation drugs—SERTIs, or Selective Endoplasmic Reticulum Translocation Inhibitors.
Our mission is simple: To alleviate diseases by selectively eliminating dysfunctional proteins at their source.
ASERTI’s Advantages
Combining AI-Enabled Drug Design with Breakthrough Screening
ASERTI’s AI-enabled drug design platform empowers rapid, efficient SERTI drug design.
A novel process for rapidly screening SERTI compounds further reduces the risk, cost, and timeline for SERTI drug development, accelerating the arrival of the next wave of medical miracles.
Collaboration is the Catalyst
ASERTI’s mission to pioneer SERTI therapeutics depends on bold, strategic partnerships. From lab benches to boardrooms, every partner plays a vital role in advancing the science and delivering medical miracles.
Partner Labs & Research Institutions
Investors & Funding Partners
Suppliers & Technology Providers
Thanks for Your Interest!